首页> 外文期刊>Ophthalmic surgery, lasers & imaging: the official journal of the International Society for Imaging in the Eye >Extrafoveal choroidal neovascularization secondary to wet age-related macular degeneration treated with intravitreal bevacizumab.
【24h】

Extrafoveal choroidal neovascularization secondary to wet age-related macular degeneration treated with intravitreal bevacizumab.

机译:玻璃体腔注射贝伐单抗治疗湿性年龄相关性黄斑变性继发的中央凹脉络膜新生血管。

获取原文
获取原文并翻译 | 示例
       

摘要

Considering the risk of recurrence of extrafoveal or juxtafoveal lesions after thermal laser treatment and the risk of poor response to photodynamic therapy, it seems reasonable to discuss with the patient the risks and benefits of antiangiogenic therapy. A case of age-related macular degeneration with an extrafoveal choroidal neovascularization treated with a single injection of intravitreal bevacizumab is described. The patient showed both anatomic and visual acuity improvement at 1 month following treatment that persisted even at the 8-month follow-up visit. Further studies are needed to validate the real risk-benefit ratio of intravitreal bevacizumab for extrafoveal exudative lesions versus the current treatments available.
机译:考虑到热激光治疗后中央凹或近中央凹病变复发的风险以及对光动力疗法反应不良的风险,与患者讨论抗血管生成疗法的风险和益处似乎是合理的。描述了一例与年龄相关的黄斑变性伴单眼玻璃体内贝伐单抗注射治疗的黄斑变性脉络膜新生血管。该患者在治疗后1个月显示出解剖学和视敏度的改善,即使在8个月的随访中也持续存在。与目前可用的治疗方法相比,需要进一步的研究来验证玻璃体腔内贝伐单抗治疗中心凹渗出性病变的真实风险收益比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号